![[UniverCité] Aspivix lève 5M$ pour accéder aux marchés européen et américain](https://republic-of-innovation.ch/wordpress/wp-content/uploads/2019/07/aspivix-630x446.jpg)
ASPIVIX, a Swiss medtech startup based at UniverCité and focused on innovations in women’s healthcare and the maker of the new generation of non-traumatic cervix stabilizer CAREVIX, announced today that it has raised $5 million in a Series A+ funding round. The round was led by HEMEX and was joined by existing investors 4FOx ventures and Zürcher Kantonalbank, as well as new investor LaunchPad APAC.
ASPIVIX will use this new investment to enter the market in Europe and US. Additionally, the company will invest in R&D to expand its existing product line and generate additional clinical data in the US. This will allow Aspivix to continue giving women gentler and safer access to gynecological procedures and contraception.
In addition, a EUREKA-EUROSTARS grant, co-funded by Innosuisse, will enable ASPIVIX to pursue new product development and strengthen its technological edge. “This grant will allow ASPIVIX to boost our research and materialize our goal for a Gynecology, now modern!” explained Julien Finci, co- founder, and CTO.